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Abstract 
Background: Malaria eradication requires a concerted approach involving all available control tools, and an effec-
tive vaccine would complement these efforts. An effective malaria vaccine should be able to induce protective 
immune responses in a genetically diverse population. Identification of immunodominant T cell epitopes will assist in 
determining if candidate vaccines will be immunogenic in malaria-endemic areas. This study therefore investigated 
whether class I-restricted T cell epitopes of two leading malaria vaccine antigens, Plasmodium falciparum circum-
sporozoite protein (CSP) and apical membrane antigen-1 (AMA1), could recall T cell interferon-γ responses from 
naturally exposed subjects using ex vivo ELISpot assays.
Methods: Thirty-five subjects aged between 24 and 43 years were recruited from a malaria-endemic urban com-
munity of Ghana in 2011, and their peripheral blood mononuclear cells (PBMCs) were tested in ELISpot IFN-γ assays 
against overlapping 15mer peptide pools spanning the entire CSP and AMA1 antigens, and 9–10mer peptide epitope 
mixtures that included previously identified and/or predicted human leukocyte antigen (HLA) class 1-restricted 
epitopes from same two antigens.
Results: For CSP, 26 % of subjects responded to at least one of the nine 15mer peptide pools whilst 17 % responded 
to at least one of the five 9–10mer HLA-restricted epitope mixtures. For AMA1, 63 % of subjects responded to at least 
one of the 12 AMA1 15mer peptide pools and 51 % responded to at least one of the six 9–10mer HLA-restricted 
epitope mixtures. Following analysis of data from the two sets of peptide pools, along with bioinformatics predictions 
of class I-restricted epitopes and the HLA supertypes expressed by a subset of study subjects, peptide pools that may 
contain epitopes recognized by multiple HLA supertypes were identified. Collectively, these results suggest that natu-
ral transmission elicits ELISpot IFN-γ activities to class 1-restricted epitopes that are largely HLA-promiscuous.
Conclusions: These results generally demonstrate that CSP and AMA1 peptides recalled ELISpot IFN-γ responses 
from naturally exposed individuals and that both CSP and AMA1 contain diverse class 1-restricted epitopes that are 
HLA-promiscuous and are widely recognized in this population.
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Background
Despite the recent gains made in the battle against 
malaria, available control strategies may not be enough 
to ensure complete elimination and eradication [1]. Vac-
cines have been a cost-effective public health tool against 
many infectious diseases and the development of anti-
malarial vaccines would be an important addition to 
existing malaria control strategies. The malaria parasite 
has a complex life cycle and it is believed that an effec-
tive anti-malarial sub-unit vaccine may need to target 
antigens in multiple stages of the parasite. Subjects in 
malaria-endemic areas develop partial immunity [2, 3] 
against severe disease and eventually against mild disease 
[4–6], and this supports the feasibility of developing vac-
cines against malaria. The role of antibodies to malaria 
antigens, especially the immunodominant circumsporo-
zoite protein (CSP) but also other liver and blood stage 
antigens, has been widely investigated [6]. But whether 
naturally acquired antibodies to CSP [7, 8], or other anti-
gens, provide protection against malaria remains elusive 
[6]. Sub-unit vaccines are being widely developed and 
the leading candidate, RTS, S which is based on the CSP, 
elicits protection in up to 50 % of subjects, but begins to 
wane after the first year [9, 10].
However, durable sterile immunity induced in humans 
by bites of radiation-attenuated Plasmodium falciparum-
infected mosquitoes [11] or injection of purified radi-
ation-attenuated sporozoites [12] is by far the strongest 
indicator of the feasibility of a malaria vaccine, and immu-
nity is likely mediated by antibodies and T cell responses 
[12]. There is as yet no clearly defined correlate of protec-
tion against clinical malaria but the immune mechanisms 
mediating protection, at least in animal models, likely 
include interferon-γ (IFN-γ)-secreting CD8 + T cells that 
primarily target malaria antigens expressed in liver stages 
[13, 14]. Therefore, a second approach has been to use 
heterologous prime-boost regimens such as DNA/human 
adenovirus-5 that target the pre-erythrocytic stages using 
CSP and apical membrane antigen-1 (AMA1) [15, 16]. A 
DNA/Ad vaccine-induced sterile immunity in 27  % of 
subjects and CD8 + T cell IFN-γ responses to CSP and 
AMA1 contributed to protection [15, 16]. Protection was 
associated with class 1-restricted epitopes, particularly in 
AMA1 [15]. These and other class 1-restricted epitopes 
have been identified in CSP and AMA1 in subjects 
immunized with gene-based vaccines [17, 18] and radia-
tion-attenuated sporozoites [19, 20] as well as in subjects 
in malaria-endemic areas [21–23].
As with antibodies, the role of naturally acquired T cell 
responses in providing protection against malaria infec-
tion or disease remains largely unanswered., although 
ELISpot IFN-gamma (IFN-γ) has been used to meas-
ure naturally acquired CD8  +  T cell responses [6, 24]. 
Recently, in a study with subjects who were naturally 
exposed to P. falciparum malaria in Ghana [25], class 
1-restricted T cell IFN-γ responses were successfully 
measured using ex  vivo ELISpot. A major finding of 
this earlier study was that peptides containing predicted 
class 1-restricted epitopes recalled ELISpot responses 
from human leukocyte antigen (HLA)-matched sub-
jects, although the frequencies of such responses were 
lower than recall responses induced by longer HLA DR-
restricted peptides [25]. However, since the magnitude 
of responses was generally low, it was essential to use an 
appropriate definition of positivity that reproducibly dis-
tinguished antigen-specific ELISpot activities induced by 
natural exposure without vaccine intervention. On this 
basis, a definition of lower stringency (at least a doubling 
of spot-forming cells/million (sfc/m) peripheral blood 
mononuclear cells (PBMC) in test wells relative to control 
wells, and a difference of at least 10 sfc/m between test 
and control wells) than that used in vaccine trials con-
ducted by the Naval Medical Research Center (NMRC) 
[26] was effective for assessing positivity of ex vivo ELIS-
pot IFN-γ responses to P. falciparum CSP and AMA1 in 
naturally exposed subjects [25]. Of the number of posi-
tive responses identified using this stringency definition, 
82  % remained positive when the positivity definition 
used for vaccine-induced responses at NMRC [26] was 
applied. This positivity definition was adapted for a study 
measuring naturally acquired ELISpot IFN-γ responses 
to the P. falciparum cell-traversal protein for ookinetes 
and sporozoites (CelTOS) in Ghana, namely a stimula-
tion index of >2.0 (response obtained with PBMCs stimu-
lated with malaria antigen peptides compared to medium 
alone) and a difference of 10 sfc/m between antigen-stim-
ulated and unstimulated PBMCs [27].
These positivity criteria were applied in the current 
study to better determine the potency of 15mer peptides 
spanning the entire sequences of the vaccine candidate 
antigens CSP (3D7) and AMA1 (3D7) for induction of 
IFN-γ recall responses in PBMCs from naturally exposed 
subjects in Ghana using ex  vivo ELISpot assays. Pep-
tide pools containing 9–10mers that represent known 
or predicted class 1-restricted epitopes and grouped 
according to HLA supertypes were also tested against 
Keywords: Circumsporozoite protein, CSP, Apical membrane antigen-1, AMA1, Natural transmission, Ghana, Ex vivo 
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subject PBMCs. This was to assess the feasibility of 
using 9–10mer pools to predict the HLA restriction of 
responses to the 15mer overlapping peptides since this 
would provide further insights into the genetic restriction 
of naturally acquired ex vivo ELISpot IFN-γ responses to 
CSP and AMA1 in the same population. Since 11 of the 
35 tested subjects had been HLA-typed, it was possible 
to determine whether such HLA-restricted pools would 
detect matched HLA-restricted responses of HLA-typed 
subjects. For subjects who were not HLA-typed, it was 
possible to use these HLA pools to examine the HLA-
restriction of positive responses in some subjects, and the 
observed activities could be best explained by the prom-
iscuity of class I-restricted epitopes [19, 28–30]. Taken 
together, the results obtained from these analyses pro-
vide evidence that a malaria vaccine containing CSP and 
AMA1 may induce broad immune responses in a geneti-
cally diverse population. These results also demonstrate 
the need to include field assessment of HLA-restricted 
epitopes in malaria vaccine design strategies.
Methods
Ethics
This study was conducted according to the human 
research protocol ‘Quality Control of Immunological 
Reagents and Validation of Improvements to Immu-
nological Assays in Support of Malaria Vaccine Trials’, 
which was approved by Institutional Review Boards at 
the Noguchi Memorial Institute for Medical Research 
(NMIMR) and the NMRC. NMIMR holds a US Govern-
ment Federal-wide Assurance (FWAA00001824) from 
the Office for Human Research Protections, as does 
NMRC (FWA00000152). NMRC also holds a Depart-
ment of Navy Addendum to the FWA for human sub-
ject protections (DoDI 3216.02). The protocol was 
conducted in accordance with the principles in The Bel-
mont Report and federal regulations regarding the pro-
tection of human subjects in research including 32 CFR 
219 (The Common Rule), and all regulations pertinent to 
the Department of Defense, the Department of the Navy, 
the Bureau of Medicine and Surgery of the US Navy 
and internal NMRC policies for human subject protec-
tions and responsible conduct of research. All NMRC 
and NMIMR personnel contributing to or perform-
ing human research were certified as having completed 
human research ethics education and training. Written 
informed consent was sought from all study subjects who 
willingly agreed to be part of the study and met the inclu-
sion criteria.
Study site
The study was conducted within the University of Ghana, 
Legon and its surrounding communities in Accra, Ghana. 
Legon is about 10 km north of Accra, the capital city of 
Ghana. It is home to the University of Ghana, and a 10 sq 
km area around Legon has an approximate population 
of 100,000. Malaria transmission is very low and limited 
mainly to the rainy season from March to November.
Participants
Study subjects were male and female adults between 24 
and 43 years (average age 29 years) who were resident in 
the study area. Eligibility criteria for the study were the 
following: age 18–55  years; males, or females who were 
not pregnant or nursing; normal screening medical his-
tory and physical examination; haemoglobin  >10  g/dL; 
absence of known immunodeficiency (>400 CD4  +  T 
cells/μL); and, negative hepatitis B and C serology. All 
participants generally had a normal medical history at 
screening and physical examination. A total of 45 sub-
jects were screened and 35 who met the inclusion criteria 
were included in the study. The 35 selected study sub-
jects were subsequently screened for malaria parasites by 
rapid diagnostic test (RDT) kits and by light microscopy.
Sample collection
Sixty ml of venous blood was collected per subject into 
heparinized tubes. PBMCs were isolated from blood by 
gradient centrifugation using Accuspin Histopaque-1077 
cell separating tubes. After washing and counting, cells 
were rested in an incubator at 37 °C, 5 % CO2 for a maxi-
mum of 20 h before use in ex vivo ELISpot assays.
HLA typing
For 11 of the 35 subjects, low-moderate resolution 
HLA typing for HLA-A and HLA-B was conducted by 
the Department of Defence Bone Marrow Donor Pro-
gramme using the ABDR SSP Unitray system (Pel-Freeze, 
Brown Deer, WI, USA) according to the manufacturer’s 
instructions, and as used previously [25].
Synthetic peptides and peptide pools
Ex vivo ELISpot IFN-γ assays used commercially syn-
thesized 15mer peptides that overlapped by 11 amino 
acids (Chiron Technologies, Clayton, Victoria, Australia). 
These 15mer peptides represented the full-length CSP 
(397 amino acids) and AMA1 (622 amino acids) anti-
gens, each from strain 3D7 [25]. These were combined 
into nine pools for CSP (Cp1-Cp9) containing three to 12 
peptides per pool, and 12 pools for AMA1 (Ap1-Ap12) 
containing ten to 13 15mer peptides per pool (Additional 
file  1: Table S1 and Additional file  2: Table S2). Class 
1-restricted HLA-binding 9–10mer peptides within CSP 
and AMA1 were predicted using NetMHC [31] or as 
previously published [17, 18] and were defined accord-
ing to their supertype classification [32]. The choice of 
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these HLA-binding peptides was on the basis that their 
predicted HLA supertypes are among the most globally 
prevalent HLA alleles [32]. The HLA-binding peptides 
were synthesized (Alpha Diagnostics Intl Inc, San Anto-
nio, TX, USA, (>91 % purity)) and grouped into peptide 
pools containing predicted 9–10mer peptides for each 
HLA supertype. Details of the mixtures of predicted 
9–10mer HLA-binding pools from the CSP and AMA1 
antigens, and the CSP or AMA1 15mer peptide pools 
in which the corresponding 9–10mer epitopes were 
contained, are presented in Table  1 (CSP) and Table  2 
(AMA1), respectively. The locations of these epitopes 
within the 15mer peptides are shown (in italics and 
bolditalics) in Additional file 1: Table S1 and Additional 
file  2: Table S2. All peptides were originally in sterile 
plain RPMI and were diluted to the required concentra-
tion with RPMI 1640 with 1  % penicillin–streptomycin, 
1 % l-glutamine and 10 % normal human serum) before 
use.
Ex vivo ELISpot IFN‑γ assays
ELISpot IFN-γ assays were performed as previously 
described [33]. Briefly, multiscreen plates (Millipore Cor-
poration, USA) were coated with 100  µl/well of 15  µg/
ml anti-human IFN-γ monoclonal antibodies (Mabtech 
AB, USA) in 0.1  M bicarbonate buffer, pH 9.6. Plates 
were incubated at 4 °C overnight, washed six times with 
RPMI 1640 and blocked for at least 2 h with assay block-
ing buffer. Plates were subsequently washed as described 
above and PBMCs (400,000 cells/well) from each subject 
were tested in duplicate with all CSP and AMA1 15mer 
peptide pools as well as with the pools of predicted 
HLA A- and B-specific peptide pools (10 μg/ml of each 
peptide in all pools). Concanavalin A (Con A, Sigma 
Aldrich, USA) (0.625  μg/ml) and CEF (Cellular Tech-
nology Ltd, USA) (2.0  μg/ml) were positive controls in 
all assays. Subject PBMCs incubated with medium only 
were used as negative controls. After PBMC incubation 
for 36 h at 37 °C, 5 % CO2, plates were washed six times 
with 250  μl/well of wash buffer (PBS containing 0.05  % 
Tween 20) and incubated with 100  μl/well of 1  μg/ml 
biotinylated anti-IFN-γ monoclonal antibody (Mabtech, 
USA) diluted in 0.5 % fetal calf serum (FCS) in PBS for 
3  h at room temperature. Plates were again washed six 
times and incubated with 100 μl/well of 1 μg/ml alkaline-
phosphatase-conjugated streptavidin (Mabtech, USA) for 
1 h at room temperature. Plates were afterwards washed 
six times as above and three times with plain PBS before 
incubation with an enzyme-specific chromogenic sub-
strate (Bio-Rad, USA) for 15  min at room temperature. 
Colour development was terminated by washing of 
plates under tap water and the plates air-dried at room 
temperature. The number of IFN-γ-producing cells in the 
form of spots per well was subsequently estimated using 
an automated ELISpot plate reader (AID GmbH, Ger-
many) and the acquired data was exported into Microsoft 
Excel for analysis.
Data analysis
Activities were calculated as sfc/m PBMCs. The assay 
was considered positive if there was (1) at least a dou-
bling of sfc/m in test wells relative to control wells, and 
(2) a difference of at least ten spots between test and con-
trol wells. This definition was adapted for use in a recent 
study that evaluated a different malaria antigen, CelTOS 
[27]. Subjects were considered positive to a malaria anti-
gen if their PBMCs tested positive against at least one 
peptide pool. All graphics were created in Microsoft 
Excel.
Results
Forty-five healthy Ghanaian adults were screened for this 
study, and 35 subjects between 24 and 43  years (aver-
age age of 29  years) who met eligibility requirements 
and gave informed consent participated in the study. All 
subjects were negative for malaria by light microscopy 
and malaria RDTs and all female subjects were not preg-
nant. For each subject, the ELISpot activity (sfc/m) for 
the unstimulated medium control was subtracted from 
the activities (sfc/m) for each test peptide. All subjects 
in this study made positive IFN-γ responses to Con A or 
CEF or both, as previously reported by Anum et al. [27]. 
In all assays, unstimulated medium control responses 
ranged between 0 and 18 sfc/m except subjects v15 and 
v28 whose mean unstimulated medium responses were 
69 and 88 sfc/m respectively.
Ex vivo ELISpot IFN‑γ responses to CSP overlapping 
peptide pools
Nine of 35 subjects (26 %) were positive with at least one 
CSP 15mer peptide pool (Fig. 1, Table 3). Of these, eight 
subjects were positive to a single 15mer pool and one 
subject was positive to two CSP 15mer pools. The high-
est number of positive responses was to Cp9 (six sub-
jects), followed by Cp1 (two subjects), and Cp4 and Cp6 
(one subject each) (Fig. 1). The highest CSP 15mer pool 
activities were to Cp9 (v01: 38 sfc/m, v10: 24 sfc/m, v14: 
18 sfc/m) and Cp4 (v23: 16 sfc/m). None of the subjects 
made positive responses to the CSP 15mer peptide pools 
Cp2, Cp3, Cp5, Cp7, and Cp8. Also, 26 subjects did not 
respond to any of the nine CSP peptide pools (Fig.  1), 
even though all subjects responded to the positive con-
trols; either Con A or CEF or both [27]. Thirteen CSP 
negative subjects were positive with AMA1 15mer pools.
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Ex vivo ELISpot IFN‑γ responses to predicted HLA‑binding 
CSP peptide pools
Six of the 35 subjects (17  %) responded positively to at 
least one of the CSP predicted HLA-binding peptide 
pools tested (Fig. 2, Table 3). Three of these subjects (v01, 
v02 and v16) were HLA-typed while the other three (v13, 
v14 and v30) were not. Of the three HLA-typed subjects, 
two were positive to a single HLA pool (v01 to the A03 
pool and v16 to the A01 pool) while the third (v02) was 
positive to three HLA pools (restricted by A01, A02 and 
A03) (Table  3). For the three subjects with unknown 
HLA types, two were positive to a single HLA pool (v13 
to the A24 pool and v30 to the B27 pool) while the third 
(v14) was positive to three HLA pools (restricted by A01, 
A02 and A24) (Table 3).
For all six positive subjects the highest number of posi-
tive responses was to HLA A01 pool (three subjects), 
HLA A02, HLA A03 and HLA A24 pools (two subjects), 
and HLA B27 pool (one subject) (Fig. 2). Thus, there were 
positive responses to all five HLA-binding CSP peptide 
pools among the six responders.
Interpretation of responses to CSP 15mer peptide pools 
and HLA pools
Seven HLA-typed and five non-HLA-typed subjects 
were positive with either CSP 15mer pools or C-HLA 
pools or both (Table  3). Three of the HLA-typed sub-
jects were positive with C-HLA pools (Table  3); two of 
these subjects were positive with C-HLA pools that con-
tained HLA-matched epitopes and one subject was posi-
tive with a C-HLA pool (A01) that contains promiscuous 
epitopes restricted by the subject’s matching HLA (A03). 
Four HLA-typed subjects were positive with CSP 15mer 
pools but negative with C-HLA pools, and these CSP 
15mer pools contain HLA matched epitopes or promis-
cuous HLA matching epitopes. This interpretation can be 
applied to three of the five non-HLA-typed subjects who 
were positive with matched and promiscuous epitopes. 
No prediction was possible for the remaining two posi-
tive but non-HLA-typed subjects.
Ex vivo ELISpot IFN‑γ responses to the AMA1 peptide pools
Twenty-two of 35 subjects (63  %) responded positively 
to at least one of the AMA1 15mer peptide pool (Fig. 3, 
Table  4), and therefore the frequency of responses to 
AMA1 was greater than to CSP (26 %). Of these, 13 sub-
jects were positive to one AMA1 15mer peptide pool, 
four subjects were positive to two peptide pools, three 
subjects were positive to three peptide pools, one subject 
was positive to four peptide pools, and one subject was 
positive to five peptide pools (Fig. 3). The highest number 
of positive responses was to Ap6 (16 subjects), Ap1 (nine 
subjects) and Ap2 (five subjects). The highest AMA1 
15mer pool activities were to Ap1 (v01: 116 sfc/m) and 
Ap6 (v01: 58  sfc/m, v14: 100  sfc/m, v17: 71  sfc/m, v28: 






































Cp9 Cp8 Cp7 Cp6 Cp5 Cp4 Cp3 Cp2 Cp1
Fig. 1 Number of IFN-γ-secreting cells in response to stimulation with the nine 15mer CSP peptide pools. Values are expressed as spot forming 
cells per million PBMCs. Stacked bars represent responses to the different Cp pools and asterisks indicate responses that met the positivity criteria as 
described in (“Methods”) section
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shows that, aside response frequencies, the magnitude 
of responses to AMA1 15mer peptides was also higher 
than that to CSP 15mer peptides since none of the CSP 
peptide responses was greater than 50 sfc/m. None of the 
AMA1 positive subjects had positive responses to pools 
Ap5, Ap9 and Ap12, and 13 subjects did not respond to 
any of the 12 AMA1 peptide pools (Fig. 3). Two AMA1 
negative subjects (v10 and v12) were positive with CSP 
pools. The unstimulated PBMC control from one subject 
(v15) had high ELISpot IFN-γ responses and this sub-
ject’s responses to almost all stimulants did not meet the 
positivity criteria despite having apparently high activi-
ties (Figs. 1, 3). 
Ex vivo ELISpot IFN‑γ responses to predicted HLA‑binding 
AMA1 peptide pools
Eighteen of the 35 subjects (51 %) responded positively to 
at least one AMA1 HLA pool (Fig. 4, Table 4). Of these 18 
subjects, 13 were positive to one A-HLA pool, four sub-
jects were positive to two A-HLA pools, and one subject 
(v14) was positive to five of the six A-HLA pools (Fig. 4, 
Table  4). The highest number of positive responses was 
Table 3 Activities to CSP peptide pools and CSP HLA peptide pools—matching activities of peptide pools
Activities of subjects to either CSP 15 mer peptide pools or CSP HLA peptide pools are shown; subjects that were negative with both sets of peptide pools were 
excluded. For each subject, the HLA supertypes that are matched by the tested peptides are italicized in bold and underlined, while predicted promiscuous epitopes 
are italicized and in bold. Positivity was defined as described in “Methods”
a Matched, where activity of a CSP HLA pool matched that subject’s HLA
b Matched through analysis of promiscuous epitopes in that positive CSP HLA pool and that match subject’s HLA
c Matched through analysis of predicted epitopes in that positive CSP pool that match that subject’s HLA
d Matched through analysis of promiscuous epitopes in that positive CSP pool that match that subject’s HLA
e In the absence of positive HLA peptide pools, no HLA prediction is possible
Subject HLA supertype CSP 15mer pool CSP HLA pool Interpretation
HLA-typed
 v01 A01 A03 B27 B27 Cp9 C-HLA A03 A03 Matcheda
A03 pool contains promiscuous A01 and B27 epitopesb
 v02 A02 A03 B27 B44 NEG C-HLA A01, C-HLA A02, 
C-HLA A03
A02, A03 Matcheda A01 pool contains promiscuous A03, 
B27 and B44 epitopesb
A02 pool contains promiscuous B27 epitopeb
A03 pool contains promiscuous B27 epitopesb
 v04 A01 A24 B27 B27 Cp1 NEG Cp1 pool contains matched identified A01, A24 and B27 
epitopesc
Cp1 pool contains matched promiscuous A01, A24 and 
B27 epitopesd
 v05 A03 A01A03 B27 B44 Cp1, Cp9 NEG Cp1 pool contains matched identified A03 and B27 
epitopesc and promiscuous A03 and B44 epitopesd
Cp9 pool contains matched identified B27 and promiscu-
ous B44 epitopesd
 v10 A02 A02 B07 B07 Cp9 NEG Cp9 pool contains matched A02 epitopesc
 v12 A01A24 A03 B07 B27 Cp6 NEG Cp6 pool contains promiscuous B07 and B27 epitopesd
 v16 A03 A03 B27 B58 Cp9 C-HLA A01 A01 pool contains promiscuous A03 and B27 epitopesb
Cp9 pool contains promiscuous A01, B27 and B58 
epitopesd
HLA not typed
 v13 NEG C-HLA A24 Probably A24 matchedb
A24 pool contains promiscuous A02, B07, B27 and B58 
epitopesb
 v14 Cp9 C-HLA A01, C-HLA A02, 
C-HLA A24
Probably A02 matched as Cp9 contains identified A02 
epitopesa,c
Cp9 pool contains promiscuous A01 and A24 epitopesd
 v30 NEG C-HLA B27 Probably B27 matcheda
B27 pool contains identified promiscuous A01A24 and 
A02 epitopes, and predicted A01, A24, , B07, B58 and 
B62 epitopesb
 v23 Cp4 NEG No HLA prediction possiblee
 v31 Cp9 NEG No HLA prediction possiblee
No. positive 9 (26%) 6 (17%)
Total Positive 12 (34%)
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to HLA A03 (11 subjects), HLA A02 (seven subjects), fol-
lowed by HLA B07 and HLA A01 (three subjects each).
Eight of these 18 positive subjects were HLA-typed while 
the remaining ten subjects were not. Of the eight HLA-typed 
subjects, six were positive to a single A-HLA pool (v02, v03, 
v12 and v16 to the A-HLA A02 pool; v05 and v19 to the 
A-HLA A03 pool), while two subjects were each positive 
to two different A-HLA pools (v01 to A-HLA A01 and B44 
pools; v10 to A-HLA A02 and A03 pools) (Table 4). For the 
ten subjects with unknown HLA types, seven were positive 
to a single A-HLA pool (v09 to the A-HLA B07 pool, v13 to 
the A-HLA A24 pool and v20, v22, v31, v32 and v33 all posi-
tive to the A-HLA A03 pool), two were positive to two dif-
ferent A-HLA pools (v06 to the A-HLA A02 and A03 pools; 
v30 to the A-HLA A03 and B07 pools), and the last subject 
(v14) was positive to all the six A-HLA pools (restricted by 
A01, A02, A03, A24, B07, and B44) that were tested (Table 4).
Interpretation of responses to AMA1 15mer pools and HLA 
pools
Eleven HLA-typed subjects and 17 non-HLA-typed sub-




































C-HLA B27 C-HLA A24 C-HLA A03 C-HLA A02 C-HLA A01
Fig. 2 Number of IFN-γ-secreting cells in response to stimulation with the five CSP HLA pools. Values are expressed as spot forming cells per million 






























































Ap12 Ap11 Ap10 Ap9 Ap8 Ap7 Ap6 Ap5 Ap4 Ap3 Ap2 Ap1
Fig. 3 Number of IFN-γ-secreting cells in response to stimulation with the 12 15mer AMA1 peptide pools. Values are expressed as spot forming 
cells per million PBMCs. Stacked bars represent responses to the different Ap pools and asterisks indicate responses that met the positivity criteria
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Table 4 Activities to AMA1 peptide pools and AMA1 HLA peptide pools—matching activities of peptide pools
Activities of subjects to either AMA1 15 mer peptide pools or AMA1 HLA peptide pools are shown; subjects that were negative with both sets of peptide pools were 
excluded. For each subject, the HLA supertypes that are matched by the tested peptides are italicized in bold and underlined, while predicted promiscuous epitopes 
are italicized and in bold. Positivity was defined as described in “Methods”
Interpretation (for HLA-typed subjects)
a Matched, where activity of an AMA1 HLA pool matched that subject’s HLA
b Matched through analysis of promiscuous epitopes in that positive AMA1 HLA pool and that subject’s HLA
c HLA-Matched through analysis of epitopes in that positive AMA1 pool that match that subject’s HLA
d HLA-Matched through analysis of promiscuous epitopes in that positive AMA1 pool that match that subject’s HLA. For non-HLA-typed subjects
e HLA-matched through analysis of epitopes in that positive AMA1 peptide pool that contain matched HLA epitopes
f HLA-matched through analysis of promiscuous epitopes in that positive AMA1 peptide pool that contain matched HLA epitopes
g In the absence of positive HLA peptide pools, no HLA prediction is possible
Subject HLA supertype AMA1 15mer pool AMA1 HLA pool Interpretation
HLA-typed
 v01 A01 A03 B27 B27 Ap1, Ap6 A01, B44 A01 Matcheda
B44 pool contains promiscuous A01 and B27 epitopesb
A01 pool contains promiscuous A03 and B27 epitopesb
Ap1 and Ap6 pools contain promiscuous A01, A03 and B27 epitopesd
 v02 A02 A03 B27 B44 NEG A02 A02 Matcheda
A02 contains promiscuous A01, A03 and B44 epitopesd
 v03 A01 A03 B07 B58 NEG A02 A02 pool contains promiscuous A01 and A03 epitopesb
 v04 A01 A24 B27 B27 Ap2, Ap6 NEG Ap2 pool contains matching A01 epitopesc
Ap6 pool contains matching A01 epitopesc, and promiscuous B27 
epitopesd
 v05 A03 A01A03 B27 B44 Ap6 A03 A03 Matcheda
A03 contains promiscuous A01A03, A03 and B27 epitopesd
 v08 A01A03 A02 B27 B44 Ap1 NEG Ap1 pool contains matching A02 and B44 epitopesc, and promiscuous B27 
epitopesd
 v10 A02 A02 B07 B07 NEG A02, A03 A02 matcheda
A03 pool contains promiscuous A02 and B07 epitopesd
 v12 A01A24 A03 B07 B27 NEG A02 A02 pool contains promiscuous A03 and B27 epitopesd
 v16 A03 A03 B27 B58 Ap2, Ap6, Ap11 A02 A02 contains promiscuous A03 and B27 epitopesd
Ap6 contains promiscuous A03, B27 and B58 epitopesd
 v17 A01A03 A03 B07 B44 Ap6 NEG Ap6 contains matching A03 and B07 epitopesc, and promiscuous A01A03 
and B07 epitopesd
 v19 A03 A24 B44 B62 NEG A03 A03 Matcheda
HLA not typed
 v06 Ap1 A02, A03 Ap1 pool contains matching A02 and A03 epitopese
 v09 Ap1, Ap6 B07 Ap1 and Ap6 pools contain matching B07 epitopese
 v13 Ap7 A24 Ap7 and A24 contains promiscuous A01, A02 and B44 epitopese,f
 v14 Ap1, Ap2, Ap6 A01, A02, A03, A24, 
B07
Ap1 pool contains matching A01, A02, A03, A24, B07 and B44 epitopese
Ap2 contains matching A01, A02 and A03 epitopese, and promiscuous B07 
epitopesf
Ap6 contains matching A01, A03 and B07 epitopes5, and promiscuous B07 
epitopesf
 v22 Ap6 A03 Ap6 pool contains matching A03 epitopese
 v30 Ap1, Ap2, Ap3, Ap6 A03, B07 Ap1, Ap2, Ap3 and Ap6 pools contain matching A03 epitopese
Ap1 and Ap6 pools contain matching B07 epitopese
 v31 Ap6 A03 Ap6 pool contains matching A03 epitopese
 v32 Ap1 A03 Ap1 pool contains matching A03 epitopese
 v33 Ap1, Ap6 A03 Ap1 and Ap6 pools contain matching A03 epitopese
 v18 Ap3, Ap4, Ap7, Ap8, Ap10 NEG No prediction possibleg
 v07 Ap1, Ap6, Ap11 NEG No prediction possibleg
 v20 NEG A03 Probably contains A03-matched epitopese
 v21 Ap2 NEG No prediction possibleg
 v23 Ap6 NEG No prediction possibleg
 v26 Ap6 NEG No prediction possibleg
 v28 Ap6 NEG No prediction possibleg
 v34 Ap6 NEG No prediction possibleg
No. positive 22 (63%) 18 (51%)
Total Positive 28 (80%)
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A-HLA pools or both (Table 4). Among the HLA-typed 
subjects, five were positive with matched A-HLA peptide 
pools, and three were positive with A-HLA pools that did 
not match their respective HLA supertypes, though these 
could be matched through promiscuous (A02) epitopes. 
This interpretation can be further extended to analysis of 
activities from three HLA-typed subjects (v04, v08 and 
v17) who were positive with the AMA1 15mer pools but 
negative with HLA pools as 15mers within the positive 
Ap pools contain matching and promiscuous epitopes. 
Thus both matching and promiscuous epitopes are rec-
ognized by these HLA-typed subjects.
For the 17 positive non-HLA-typed subjects, nine sub-
jects were positive with both AMA1 15mer pools and 
A-HLA pools and eight of these subjects recognized pre-
dicted and promiscuous epitopes in the A-HLA pools 
that match the positive AMA1 15mer pools. This was 
not the case for the ninth subject (v13) who was posi-
tive with the Ap7 and A-HLA A24 peptide pools since 
there are no predicted HLA A24 epitopes in pool Ap7. 
The two pools however contain promiscuous epitopes 
that are restricted by the HLA supertypes A01, A02 and 
B44. One non-typed subject (v20) was negative with the 
AMA1 15mer pool but positive with the HLA A03 pool, 
suggesting that v20 expressed HLA A03. No prediction 
of the HLA-restriction was possible with the remain-
ing seven subjects that were positive with AMA1 15mer 
pools but not the A-HLA pools. These outcomes col-
lectively suggest that it is possible to identify the HLA-
restriction of responses to AMA1 epitopes in the absence 
of HLA-typing in 10 of 17 (59  %) non-HLA-typed sub-
jects. Taken together, these results suggest that positive 
activities of most subjects are detected by both peptide 
pools spanning regions of CSP or AMA1 or by HLA-spe-
cific peptide pools, but epitope promiscuity makes a sig-
nificant contribution to determining agreement between 
positive CSP or AMA1 15mer peptide pools and HLA 
peptide pools.
Discussion
Development of a malaria vaccine will add to currently 
available malaria prevention and control tools and greatly 
enhance ongoing elimination and eradication efforts. 
Identification of immunodominant T cell epitopes within 
malaria vaccine target antigens may be important for 
determining whether malaria vaccines would induce 
protection in a genetically diverse population. An initial 
human trial with a DNA-prime adenovirus-boost malaria 
vaccine using CSP and AMA1 achieved 27 % efficacy [16] 
and this strategy is being developed further to improve 
efficacy. Immunity to malaria develops in endemic 
regions, and is often related to intensity and seasonality 
of exposure to infected mosquitoes [34]. While naturally 
acquired immune responses have been better character-
ized in areas of high transmission [35, 36], only a few 
studies have shown that natural malaria transmission in 
areas of lower endemicity also induces significant but 
low ELISpot activities to antigens such as CSP, CelTOS 
and AMA1 at these sites [25, 27] and that it is possible 
to measure these reproducibly using positivity criteria 
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A-HLA B44 A-HLA B07 A-HLA A24 A-HLA A03 A-HLA A02 A-HLA A01
Fig. 4 Number of IFN-γ-secreting cells in response to stimulation with the six AMA1 HLA pools. Values are expressed as spot forming cells per mil-
lion PBMCs. Stacked bars represent responses to the different A-HLA pools and asterisks indicate responses that met the positivity criteria
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of appropriate stringency that was lower than that used 
to define high vaccine-induced responses. The aim of 
this study was to assess 15mer peptides that cover the 
entire sequences of CSP and AMA1, as well as predicted/
known HLA class I-restricted epitopes from the same 
antigens, for their ability to induce IFN-γ recall responses 
in PBMCs from naturally exposed individuals in Ghana, 
and to better determine optimal reagents for further site 
characterization.
These results show that pools of 15mer peptides span-
ning the full length of the CSP and AMA1 antigens recall 
IFN-γ responses in adults, and that these responses are 
approximately twice as frequent for AMA1 compared to 
CSP. This confirms and extends data from two previous 
studies in the same site (Legon) which used ex vivo ELIS-
pot to measure activities to CSP and AMA1 [25, 27]. The 
first study tested the reproducibility of ex  vivo ELISpot 
in areas of natural malaria transmission, where activities 
were low, and there were fewer positive responses to CSP 
than to AMA1 when the same Ap and Cp peptide pools 
described in the current study were used to stimulate 
subject PBMCs [25]. Similar observations of relatively 
lower CSP responses were made in the second study [27] 
where PBMCs were stimulated with single pools contain-
ing all CSP or all AMA1 15mer peptides. It has however 
been shown in a previous DNA/Ad vaccine trial that sin-
gle pools containing overlapping peptides that span an 
entire antigen recall lower ex vivo ELISpot activities than 
summed activities of multiple peptide pools, each con-
taining fewer peptides [15, 16]. Individual smaller pep-
tide pools are therefore optimal for the characterization 
of CD8  +  T Cell IFN-γ responses in potential vaccine 
study sites.
The greater activity of AMA1 compared to CSP results 
from long-term exposure of subjects to AMA1, which is 
also found in blood stages, during natural malaria trans-
mission [37–40]. In addition, AMA1 (622 amino acids) 
is larger than CSP (397 amino acids) and is predicted to 
contain relatively more epitopes and a greater number of 
immunodominant epitopes compared to CSP (personal 
observations).
The most frequent responses to CSP were to Cp9 fol-
lowed by Cp1, and the most frequent responses to AMA1 
were to Ap6 followed by Ap1 and Ap2. This differs from 
earlier observations in Ghana where the most frequent 
responses were to Cp1, Ap7 and Ap9 [25]. In this ear-
lier study [25], conducted with subjects from Mampong 
in the Eastern Region of Ghana, smaller CSP HLA pep-
tide pools, or individual HLA peptides, elicited positive 
responses in 7/19 (36 %) subjects compared to 6/35 (17 %) 
in this study. It is not known whether this reflects differ-
ences in HLA types of the study subjects, or other fac-
tors, such as malaria transmission intensity. Mampong, 
the site of the earlier study, is a semi-urban community 
about 35  km from Accra [25] and has higher transmis-
sion intensity than Legon. A study in a seasonal malaria 
transmission area in Kenya found no seasonal differences 
in the frequency of IFN-γ and IL5 ELISpot responses, 
but higher frequencies of ELISpot responses to IL10 and 
TNF during the high transmission season compared to 
the low transmission season [41]. Another study by the 
same group also found no differences in adult IFN-γ 
responses between transmission seasons [42]. The role of 
malaria transmission intensity on the frequency of IFN-γ 
responses therefore requires further investigation, and 
future studies may need to factor malaria transmission 
intensity into site selection for the possibility of identify-
ing additional immunodominant peptides.
Studies using PBMCs from malaria-naïve subjects 
immunized with adenovirus-vectored AMA1 and CSP 
candidate vaccines found the highest responses against 
Cp1, Cp2, Cp6 and Cp9 for CSP [17], and Ap1, Ap3, Ap4, 
Ap7, Ap8, Ap10 and Ap11 for AMA1 [18]. Thus, posi-
tive responses to peptide pools Ap2, Ap6 and Cp4 were 
observed in the current study but not in studies with 
malaria-naïve subjects immunized with the gene-based 
vaccine [16–18]. These differences may be attributable 
to the genetic (HLA) background of subjects exposed 
to multiple strains of P. falciparum by natural transmis-
sion or by vaccine immunization with one strain, 3D7. 
Subjects in malaria-endemic areas have most likely been 
repeatedly exposed to a diversity of parasite strains and 
may thus recognize a broader repertoire of immunodom-
inant peptides. This study only investigated responses to 
CSP and AMA1 that are undergoing T cell-based vac-
cine development (16–18). However, T cell epitopes have 
been identified in other antigens such as LSA1 in Kenya 
[41, 43] and Madagascar [44], and were associated with a 
delay in parasitaemia after chemotherapy in Kenya [40]. 
Similarly, T cell responses to pre-erythrocytic antigens 
were identified in studies in Gambia [22], and memory 
responses to TRAP were associated with significantly 
reduced incidence of malaria [45]. These studies, along 
with those reported here argue for a more comprehen-
sive investigation of the association of naturally-acquired 
T cell responses to malaria antigens and resistance to 
malaria infection and disease. This may be especially 
true as naturally acquired immunity may result in fewer 
malaria episodes based on the entomological inocula-
tion rate [6, 46, 47]. However, a previous study in Mali 
suggested that repeated P. falciparum infections do not 
induce sterile protection [48], suggesting that further 
studies, especially in sites for likely malaria vaccine trials, 
are warranted.
It has been suggested that immunodominant T cell 
epitopes are mostly localized to more conserved regions 
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of AMA1 and that the most polymorphic regions of 
AMA1 are poorly immunogenic [37]. The most frequent 
AMA1 pool responses in this study were to Ap6, Ap1 
and Ap2; Ap6 contains at least nine polymorphic resi-
dues, whereas Ap1 and Ap2 are generally conserved [37]. 
However, the most polymorphic regions are contained 
in Ap4 and Ap5 that did not recall responses, in general 
agreement with the earlier findings [37]. These observa-
tions collectively support the need for inclusion of field 
assessment of antigen peptides in the search for relevant 
immunodominant peptides for vaccine formulation.
The current study also investigated whether epitope 
promiscuity was reflected in the epitope-specificity of 
subjects with natural exposure to P. falciparum. Predicted 
HLA-binding peptide pools, in contrast to the 15mer 
pools, recalled fewer positive responses than the Cp or 
Ap pools. This is not a surprise, given that there were 
much fewer peptides included in the HLA-specific pools 
(Additional file  1: Table S1 and Additional file  2: Table 
S2). For subjects that were not HLA-typed, by screening 
with a series of predicted HLA-binding peptide pools, 
it was possible to identify putative HLA restrictions for 
immunodominant epitopes based on the observed and 
expected ELISpot activities (Tables 3 and 4). A major fac-
tor in determining the specificity of these HLA pools was 
promiscuity of class I-restricted epitopes and this allowed 
for a more complete interpretation of the activities of the 
HLA peptide pools, even in the absence of HLA-typing. 
Similar observations of promiscuity in such epitopes have 
been reported previously [19, 29, 30]. Promiscuity in class 
I-restricted epitopes may potentially be important for 
broad immune coverage as promiscuous epitopes can be 
recognized by multiple HLA types (Tables 1 and 2). Prom-
iscuity may however be underestimated here since only 
individual HLA supertypes rather than HLA alleles are 
included. Studies that aim to identify immunodominant 
epitopes require HLA-typing of subjects, but these results 
suggest that it may be possible to use pools of predicted 
HLA-binding peptides to detect potential immunodomi-
nant epitopes without the requirement for HLA-typing 
and strengthen the argument for inclusion of epitopes 
from multiple parasite antigens to ensure broad coverage 
of protective responses in endemic populations [24].
Of the 11 HLA-typed subjects, the HLA supertypes 
that the predicted epitopes bind to are amongst the most 
predominant HLA supertypes known globally [32]. How-
ever, a better picture of the degree of epitope promiscu-
ity and how this affects class 1-restricted responses to 
CSP and AMA1 will require HLA-typing of test subjects. 
HLA typing and testing of a greater number of subjects 
to assess epitope promiscuity and association of epitope-
specific responses with protection from clinical malaria 
is planned for further studies in Ghana. These results 
collectively suggest that vaccines containing CSP and 
AMA1 may induce effective T cell responses in a geneti-
cally diverse population.
Conclusions
In summary, the study has demonstrated the induction of 
antigen-specific responses in individuals with a history of 
natural exposure to P. falciparum. Peptides in pools Ap1, 
Ap2, Ap6, Cp1 and Cp9, in addition to other pools that 
have elicited positive responses from subjects in other 
studies, therefore require further evaluation. The data 
also demonstrate the presence of promiscuous HLA class 
I-restricted epitopes in CSP and AMA1. These epitopes 
can be recognized by multiple HLA class I types and 
may thus induce T cell responses in a genetically diverse 
population, which demonstrates the need to include field 
assessment of HLA-restricted epitopes in malaria vaccine 
design strategies. Epitopes identified in these areas will 
also be useful as standard reagents for the assessment of 
CD8 + T cell responses in vaccine trials.
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